研究单位：[1]Shanghai East Hospital[2]Beijing InnoCare Pharma Tech Co., Ltd.[3]Anhui Provincial Hospital,Hefei,Anhui,China,230036[4]Cancer Hospital, Chinese Academy of Medical Sciences,Beijing,Beijing,China,100021[5]Peking Union Medical College Hospital,Beijing,Beijing,China,100032[6]Beijing Youan Hosptital,Capital Medical University,Beijing,Beijing,China,100069[7]Beijing Cancer Hospital,Beijing,Beijing,China,100142[8]Beijing Hospital,Beijing,Beijing,China,100730[9]Fujian Cancer Hospital,Fujian,Fujian,China,350011[10]Fujian Medical University Union Hospital,Fuzhou,Fujian,China,350001[11]Mengchao hepatobiliary Hospital of FuJian Medical university,FuZhou,Fujian,China,350025[12]Foshan First People's Hospital,Foshan,Guangdong,China,528000[13]Sun Yat-sen Memorial Hospital,Guangzhou,Guangdong,China,510000[14]Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China,510060[15]ZhuJiang Hospital of Southern Medical University,Guangzhou,Guangdong,China,510280[16]Hebei Medical University Fourth Hospital,Shijiazhuang,Hebei,China,050011[17]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China,150081[18]Henan Cancer Hospital,Zhengzhou,Henan,China,450003[19]First Affiliated Hospital of Zhengzhou University.,Zhengzhou,Henan,China,450066[20]Zhongnan Hospital of Wuhan University,Wuhan,Hubei,China,430062[21]Hubei Cancer Hospital,Wuhan,Hubei,China,430079[22]Human Provincial People''s Hospital,Changsha,Hunan,China,410002[23]Hunan Cancer Hospital,Changsha,Hunan,China,410013[24]The Third Xiangya Hospital of Central South Uninversity,Changsha,Hunan,China,410013[25]Changzhou Tumor Hospital,Changzhou,Jiangsu,China,213000[26]Jiangyin Renmin Hospital,Jiangyin,Jiangsu,China,214499[27]The Affiliated Hospital of Nanjing University Meidical School,Nanjing,Jiangsu,China,210000[28]The Second Affiliated Hospital of Soochow University,Suzhou,Jiangsu,China,215004[29]Xuzhou Central Hospital,Xuzhou,Jiangsu,China,221009[30]The Second Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China,330000[31]Shengjing Hospital of China Medical University,Shenyang,Liaoning,China,110004[32]Liaoning Cancer Hospital&Institute,Shenyang,Liaoning,China,110042[33]Jiangxi Cancer Hospital,Nanchang,Nanchang,China,330029[34]General Hospital of Ningxia Medical University,Yinchuan,Ningxia,China,750004[35]Tangdu Hospital of the Fourth Military Medical University,Xi''an,Shaanxi,China,710038[36]Qilu Hospital,Jinan,Shandong,China,250012[37]Jinan Central Hospital,Jinan,Shandong,China,250013[38]Affiliated Cancer Hospital of Shandong First Medical University,Jinan,Shandong,China,250117[39]ZhongShan Hospital,Shanghai,Shanghai,China,200123[40]The Third Affiliated Hospital of Naval Medical University,Shanghai,Shanghai,China,200433[41]Sichuan Cancer Hospital,Chengdu,Sichuan,China,610041[42]West China Hospital of Sichuan University,Chengdu,Sichuan,China,610041[43]Tianjin Cancer Hospital,Tianjin,Tianjin,China,300060[44]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China,310005[45]Shulan（Hangzhou） Hospital,Hangzhou,Zhejiang,China,310009[46]The First Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou,Zhejiang,China,310009
研究目的：
This is a single-arm, open-label, multi-center phase 2 clinical trial of ICP-192. The purpose of this study is to evaluate the efficacy and safety in patients with FGFR2-Rearranged unresectable or metastatic intrahepatic cholangiocarcinoma who failed prior therapy
